Detalles de la búsqueda
1.
Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
Mult Scler;
27(6): 883-894, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32716690
2.
Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.
J Neurol Neurosurg Psychiatry;
90(12): 1324-1330, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31611264
3.
The disease-ameliorating function of autoregulatory CD8 T cells is mediated by targeting of encephalitogenic CD4 T cells in experimental autoimmune encephalomyelitis.
J Immunol;
191(1): 117-26, 2013 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23733879
4.
Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis.
Clin Immunol;
147(2): 105-19, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23578552
5.
COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy.
Neurol Ther;
12(2): 687-700, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36792812
6.
Whole blood miRNAs in relapsing MS patients treated with dimethyl fumarate in the phase 4 TREMEND trial.
J Neuroimmunol;
381: 578145, 2023 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37393851
7.
Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis.
Neurol Ther;
12(1): 145-159, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36334241
8.
Humoral immune response after Ad26.COV2.S vaccination in patients with multiple sclerosis treated with natalizumab.
Mult Scler J Exp Transl Clin;
9(4): 20552173231218117, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38089563
9.
Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies.
Neurol Ther;
12(3): 883-897, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37061656
10.
Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab.
Mult Scler Relat Disord;
63: 103921, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35700674
11.
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
Adv Ther;
39(4): 1810-1831, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35211872
12.
Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis.
J Autoimmun;
36(2): 115-24, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21257291
13.
Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence.
Neurol Ther;
10(1): 349-360, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33846959
14.
A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod.
Ther Adv Neurol Disord;
14: 17562864211021177, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34262613
15.
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex).
CNS Drugs;
35(7): 743-767, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34228301
16.
Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl Fumarate.
Int J MS Care;
23(6): 239-244, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-35035294
17.
Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Mult Scler Relat Disord;
51: 102935, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33882426
18.
A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers.
Mult Scler Relat Disord;
51: 102861, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33773271
19.
Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND.
Neurol Ther;
10(1): 169-182, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33225410
20.
Immune regulatory CNS-reactive CD8+T cells in experimental autoimmune encephalomyelitis.
J Autoimmun;
35(1): 33-44, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20172692